Legal Process Presented In Ryan Report Requires Reconsideration

Since their release earlier this year, the recommendations of the congressionally chartered Commission on Research Integrity (CRI) have generated ongoing controversy (B. Goodman, The Scientist, Jan. 22, 1996, page 1; B. Goodman, The Scientist, July 22, 1996, page 3). It should surprise no one that the report containing those recommendations has been the subject of much debate. The commission, chaired by Kenneth Ryan, was required by its charter to perform a difficult balancing act: juggling th

Written byDan Burk
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Since their release earlier this year, the recommendations of the congressionally chartered Commission on Research Integrity (CRI) have generated ongoing controversy (B. Goodman, The Scientist, Jan. 22, 1996, page 1; B. Goodman, The Scientist, July 22, 1996, page 3). It should surprise no one that the report containing those recommendations has been the subject of much debate. The commission, chaired by Kenneth Ryan, was required by its charter to perform a difficult balancing act: juggling the interests of the scientific community, the public, and various governmental agencies. Amid such acrobatics, any of these constituencies might have found their particular interest was fumbled or even dropped, and none of them could possibly receive the center-stage attention that they expected.

What might instead surprise members of the scientific community is the degree to which the commission's report shifts the balance between legal and scientific interests in misconduct inquiries. To appreciate this dramatic ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies